Table 3. Adapted table of a proposed consensus for designing the next generation of clinical trials in medulloblastoma (Ramaswamy et al. ¹⁴).

Medulloblastoma patient subgroups → genome-wide methylation array → molecularly informed clinical trial or other validated methods

Tissue collection from all patients → snap-frozen and paraffin-embedded tumor tissue, blood, and CSF

All patients require tumor board planning for a clinical trial registry: neuroimaging, neuropathology, and radiotherapy

Treatment-related side effects in all patients in the short and long term: quality-of-life measures and neuropsychological outcomes

Recurrent disease: tumors should be re-biopsied if the diagnosis was unclear, or 2 years after the initial diagnosis, or before using targeted therapy for 2 years

Extent of resection: neurosurgeons should aim for maximal safe removal

CSF, cerebrospinal fluid.